NewLimit Secures $130 Million Series B Funding to Advance Anti-Aging Research

Biotechnology firm NewLimit has received a significant $130 million Series B funding round, led by the renowned venture capital firm Kleiner Perkins. This investment underscores the potential of NewLimit’s research in longevity biotechnology, specifically its focus on epigenomic advancements. The funding, which brings NewLimit’s valuation to $810 million as of May 6, 2025, will accelerate the development of groundbreaking anti-aging solutions. Key figures behind this venture include Brian Armstrong, CEO of Coinbase and investor/board member, alongside Jacob Kimmel and Blake Byers.